e-Therapeutics plc Director/PDMR Shareholding (0163G)

TIDMETX

RNS Number : 0163G

e-Therapeutics plc

23 May 2017

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 23 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it received notification on 22 May 2017 from one of its directors, Trevor Jones, that he had purchased 59,400 shares in the Company at a price of 8.25 pence per share. This purchase took place on 12 May 2017. His resultant holding in the Company is now 166,897 shares representing 0.06 per cent. of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------- 
a)  Name                        Trevor Mervyn Jones 
    --------------------------  ------------------------------------------ 
2   Reason for the notification 
    ---------------------------------------------------------------------- 
a)  Position/status             Non-Executive Director 
    --------------------------  ------------------------------------------ 
b)  Initial notification/       Initial notification 
     Amendment 
    --------------------------  ------------------------------------------ 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------- 
a)  Name                        e-Therapeutics plc 
    --------------------------  ------------------------------------------ 
b)  LEI                         21380049RHSSJXWKYT18 
    --------------------------  ------------------------------------------ 
4   Details of the transaction(s): section to be repeated for (i) 
     each type of instrument; (ii) each type of transaction; (iii) 
     each date; and (iv) each place where transactions have been 
     conducted 
    ---------------------------------------------------------------------- 
a)  Description of the          Ordinary Shares of 0.1 pence 
     financial instrument, 
     type of instrument          ISIN: GB00B2823H99 
     Identification code 
    --------------------------  ------------------------------------------ 
b)  Nature of the transaction   Purchase of shares 
    --------------------------  ------------------------------------------ 
c)  Price(s) and volume(s)      59,400 ordinary shares at a price of 8.25 
                                 pence per share 
    --------------------------  ------------------------------------------ 
d)  Aggregated information      N/A 
     - Aggregated volume 
     - Price 
    --------------------------  ------------------------------------------ 
e)  Date of the transaction     12 May 2017 
    --------------------------  ------------------------------------------ 
f)  Place of the transaction    London Stock Exchange, AIM (XLON) 
    --------------------------  ------------------------------------------ 
 

For further information, please contact:

 
 e-Therapeutics plc                   Tel: [phone] 
  Iain Ross, Chairman                  125 
  Steve Medlicott, Finance Director    www.etherapeutics.co.uk 
 Numis Securities Limited             Tel: [phone] 
  Michael Meade / Freddie Barnfield    www.numis.com 
  (Corporate Finance) 
  James Black (Corporate Broking) 
 Instinctif Partners                  Tel: [phone] 
  Melanie Toyne Sewell / Alex Shaw     Email: [e-mail] 
 

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFLEEVIVFID

(END) Dow Jones Newswires

May 23, 2017 11:22 ET (15:22 GMT)